UBS Group’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $171M | Buy |
305,167
+20,215
| +7% | +$13M | 0.03% | 694 |
|
|
2025
Q4 | $193M | Sell |
284,952
-65,941
| -19% | -$44.9M | 0.03% | 594 |
|
|
2025
Q3 | $224M | Sell |
350,893
-22,118
| -6% | -$13.4M | 0.04% | 522 |
|
|
2025
Q2 | $200M | Sell |
373,011
-3,532
| -0.9% | -$1.69M | 0.03% | 535 |
|
|
2025
Q1 | $158M | Buy |
376,543
+44,458
| +13% | +$19.3M | 0.03% | 639 |
|
|
2024
Q4 | $137M | Buy |
332,085
+102,908
| +45% | +$45.1M | 0.03% | 713 |
|
|
2024
Q3 | $116M | Buy |
229,177
+7,412
| +3% | +$3.6M | 0.03% | 656 |
|
|
2024
Q2 | $108M | Buy |
221,765
+14,934
| +7% | +$7.5M | 0.03% | 618 |
|
|
2024
Q1 | $112M | Sell |
206,831
-2,607
| -1% | -$1.42M | 0.03% | 598 |
|
|
2023
Q4 | $116M | Buy |
209,438
+25,409
| +14% | +$11.9M | 0.03% | 512 |
|
|
2023
Q3 | $80.5M | Buy |
184,029
+43,742
| +31% | +$21.8M | 0.03% | 588 |
|
|
2023
Q2 | $70.5M | Buy |
140,287
+19,646
| +16% | +$9.41M | 0.02% | 642 |
|
|
2023
Q1 | $60.3M | Sell |
120,641
-151
| -0.1% | -$72.3K | 0.02% | 687 |
|
|
2022
Q4 | $49.3M | Buy |
120,792
+59,393
| +97% | +$23.1M | 0.02% | 806 |
|
|
2022
Q3 | $20M | Sell |
61,399
-45,884
| -43% | -$16.9M | 0.01% | 1277 |
|
|
2022
Q2 | $37.6M | Sell |
107,283
-19,077
| -15% | -$7.78M | 0.02% | 904 |
|
|
2022
Q1 | $69.1M | Sell |
126,360
-63,329
| -33% | -$33.3M | 0.02% | 681 |
|
|
2021
Q4 | $125M | Sell |
189,689
-16,104
| -8% | -$10.1M | 0.04% | 510 |
|
|
2021
Q3 | $128M | Buy |
205,793
+45,772
| +29% | +$30.8M | 0.04% | 451 |
|
|
2021
Q2 | $101M | Sell |
160,021
-1,156
| -0.7% | -$638K | 0.03% | 515 |
|
|
2021
Q1 | $78.9M | Buy |
161,177
+19,782
| +14% | +$9.91M | 0.03% | 605 |
|
|
2020
Q4 | $70.7M | Buy |
141,395
+20,366
| +17% | +$9.11M | 0.02% | 619 |
|
|
2020
Q3 | $47.6M | Sell |
121,029
-6,592
| -5% | -$2.44M | 0.02% | 676 |
|
|
2020
Q2 | $42.1M | Buy |
127,621
+5,410
| +4% | +$1.57M | 0.02% | 686 |
|
|
2020
Q1 | $29.6M | Sell |
122,211
-12,035
| -9% | -$3.14M | 0.01% | 780 |
|
|
2019
Q4 | $35.1M | Buy |
134,246
+25,524
| +23% | +$6.73M | 0.01% | 990 |
|
|
2019
Q3 | $29.6M | Sell |
108,722
-2,183
| -2% | -$607K | 0.01% | 992 |
|
|
2019
Q2 | $30.5M | Sell |
110,905
-8,381
| -7% | -$2.06M | 0.01% | 947 |
|
|
2019
Q1 | $26.7M | Buy |
119,286
+43,743
| +58% | +$9.03M | 0.01% | 975 |
|
|
2018
Q4 | $14.1M | Sell |
75,543
-85,208
| -53% | -$17.5M | 0.01% | 1330 |
|
|
2018
Q3 | $40.1M | Buy |
160,751
+8,399
| +6% | +$2.04M | 0.02% | 785 |
|
|
2018
Q2 | $33.2M | Buy |
152,352
+3,763
| +3% | +$775K | 0.01% | 876 |
|
|
2018
Q1 | $28.4M | Buy |
148,589
+14,187
| +11% | +$2.62M | 0.01% | 933 |
|
|
2017
Q4 | $21M | Buy |
134,402
+6,771
| +5% | +$1.07M | 0.01% | 1168 |
|
|
2017
Q3 | $19.8M | Sell |
127,631
-31,895
| -20% | -$5.04M | 0.01% | 1105 |
|
|
2017
Q2 | $25.8M | Buy |
159,526
+87,493
| +121% | +$14.2M | 0.01% | 891 |
|
|
2017
Q1 | $11.1M | Buy |
72,033
+15,718
| +28% | +$2.17M | 0.01% | 1405 |
|
|
2016
Q4 | $6.6M | Sell |
56,315
-20,336
| -27% | -$2.32M | ﹤0.01% | 1845 |
|
|
2016
Q3 | $8.64M | Buy |
76,651
+13,087
| +21% | +$1.38M | 0.01% | 1539 |
|
|
2016
Q2 | $5.9M | Sell |
63,564
-4,782
| -7% | -$411K | ﹤0.01% | 1800 |
|
|
2016
Q1 | $5.35M | Buy |
68,346
+1,723
| +3% | +$124K | ﹤0.01% | 1808 |
|
|
2015
Q4 | $4.86M | Buy |
66,623
+4,608
| +7% | +$329K | ﹤0.01% | 1988 |
|
|
2015
Q3 | $4.61M | Buy |
62,015
+10,657
| +21% | +$763K | ﹤0.01% | 1993 |
|
|
2015
Q2 | $3.29M | Sell |
51,358
-3,562
| -6% | -$247K | ﹤0.01% | 2498 |
|
|
2015
Q1 | $4.24M | Sell |
54,920
-4,498
| -8% | -$350K | ﹤0.01% | 2210 |
|
|
2014
Q4 | $4.41M | Buy |
+59,418
| New | +$4.17M | ﹤0.01% | 2207 |
|
Other funds holding IDXX
VCM
VPM
UBS Group's IDXX Position: Q1 2026 in Review
UBS Group increased its Idexx Laboratories (IDXX) stake by 7.1% in Q1 2026, buying an estimated $13M and bringing the position to 305,167 shares worth $171M. The position accounts for 0.03% of the portfolio, ranked #694.
UBS Group first reported a position in IDXX in Q4 2014 and has held it in 46 quarters since. The position peaked at $224M in Q3 2025. 1,312 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- UBS Group held 305,167 shares of Idexx Laboratories worth $171M as of Q1 2026.
- UBS Group bought 20,215 Idexx Laboratories shares in Q1 2026, an estimated $13M.
- Idexx Laboratories made up 0.03% of UBS Group's portfolio in Q1 2026, its #694 holding.
- UBS Group first reported a position in Idexx Laboratories in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Idexx Laboratories position peaked at $224M in Q3 2025.
- 1,312 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.